These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 33476146)
21. Evolutionary variation and adaptation in a conserved protein kinase allosteric network: implications for inhibitor design. Oruganty K; Kannan N Biochim Biophys Acta; 2013 Jul; 1834(7):1322-9. PubMed ID: 23499783 [TBL] [Abstract][Full Text] [Related]
22. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases. Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814 [TBL] [Abstract][Full Text] [Related]
23. Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases. Cox KJ; Shomin CD; Ghosh I Future Med Chem; 2011 Jan; 3(1):29-43. PubMed ID: 21428824 [TBL] [Abstract][Full Text] [Related]
24. Proteus in the world of proteins: conformational changes in protein kinases. Rabiller M; Getlik M; Klüter S; Richters A; Tückmantel S; Simard JR; Rauh D Arch Pharm (Weinheim); 2010 Apr; 343(4):193-206. PubMed ID: 20336692 [TBL] [Abstract][Full Text] [Related]
25. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Dar AC; Shokat KM Annu Rev Biochem; 2011; 80():769-95. PubMed ID: 21548788 [TBL] [Abstract][Full Text] [Related]
26. Exploration and Comparison of the Geometrical and Physicochemical Properties of an αC Allosteric Pocket in the Structural Kinome. Sturm N; Tinivella A; Rastelli G J Chem Inf Model; 2018 May; 58(5):1094-1103. PubMed ID: 29697977 [TBL] [Abstract][Full Text] [Related]
27. Recent Advances in the Discovery of CK2 Allosteric Inhibitors: From Traditional Screening to Structure-Based Design. Chen X; Li C; Wang D; Chen Y; Zhang N Molecules; 2020 Feb; 25(4):. PubMed ID: 32079098 [TBL] [Abstract][Full Text] [Related]
30. Interrogating Regulatory Mechanisms in Signaling Proteins by Allosteric Inhibitors and Activators: A Dynamic View Through the Lens of Residue Interaction Networks. Astl L; Tse A; Verkhivker GM Adv Exp Med Biol; 2019; 1163():187-223. PubMed ID: 31707705 [TBL] [Abstract][Full Text] [Related]
31. Allosteric Modulator Discovery: From Serendipity to Structure-Based Design. Lu S; He X; Ni D; Zhang J J Med Chem; 2019 Jul; 62(14):6405-6421. PubMed ID: 30817889 [TBL] [Abstract][Full Text] [Related]
32. Drug discovery and the human kinome: recent trends. Eglen R; Reisine T Pharmacol Ther; 2011 May; 130(2):144-56. PubMed ID: 21256157 [TBL] [Abstract][Full Text] [Related]
33. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2. Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186 [TBL] [Abstract][Full Text] [Related]